Cellular Intelligence, Backed by Zuckerberg, Acquires Novo Nordisk's Parkinson’s Cell Therapy STME-PD

Last year, after Novo Nordisk announced a large-scale restructuring, the development of the cell therapy project was suspended.

Advanced biotechnological forces such as cell therapy are shifting towards emerging AI healthcare companies.

On May 11 local time, Somite Therapeutics, a biotechnology company established just over two years ago, announced the acquisition of an investigational Parkinson's cell therapy from the Danish pharmaceutical giant Novo Nordisk.

Cellular Intelligence, known in English as SOMITE THERAPEUTICS, is an AI-driven cell therapy company invested in by Silicon Valley giant Meta founder Zuckerberg. It secured over $60 million from investors, including Zuckerberg, during its early funding rounds.

According to reports, the latest cell therapy acquired by the company is Novo Nordisk's STME-PD project, an allogeneic cell therapy for Parkinson’s disease treatment. It has already received U.S. FDA Investigational New Drug (IND) approval and has been granted Fast Track designation, with preparations underway for Phase II clinical trials.

The company also stated that, as part of this transaction, Novo Nordisk will make a strategic investment in SOMITE THERAPEUTICS. Last year, after announcing a large-scale restructuring, Novo Nordisk halted the development of its cell therapy projects.

Currently, cell therapy technology is rapidly evolving and showing potential in areas like Parkinson's disease and Alzheimer's disease, where no effective treatments currently exist. Researchers hope to use stem cells to replace the dysfunctional cells lost by patients, such as the neurons that lose their ability to produce dopamine in Parkinson’s disease.

Micha Breakstone, co-founder and CEO of SOMITE THERAPEUTICS, is a serial entrepreneur in AI biotechnology. In a statement, Breakstone said: "This acquisition marks the beginning of an AI-native era for cell therapy, where biology no longer dictates fate but can be designed and rewritten."

Cell therapy has long shown extraordinary potential but has also been limited by its complexity. The difficulty in production and manufacturing, coupled with biological characteristics that are highly dependent on specific environments, means the development of potential therapies still relies too heavily on experience, is slow-moving, and requires repeated trial and error.

Against this backdrop, AI can play a significant role. Breakstone stated that Parkinson's disease is a critical unmet medical need, and the goal of AI is to make cell therapy more predictable, scalable, and controllable. The combination of both can transform cell therapy from an empirical process into a predictive engineering discipline.